Join Now
Sign In
Would you share the latest news on how genetics is influencing the treatment of brain cancer?
Topic Tags:
Topic Tags:
Diseases:
Diseases:
1
Expert Answers
MineshMehtaMD (Physician - Oncology - Radiation (Verified) ) - 07 / 05 / 2012
The unraveling of the human genome has led to the cancer genome atlas project, in which detailed genetic analysis of several cancers/tumors is being pursued. Glioblastoma was one of the early candidate tumors for this effort and the recent seminal publications outlining the genetic make-up of this tumor has provided us with several significant insights which can be summarized as follows:
A. Unlike some other tumors, GBM is characterized by multiple genetic modifications, and is rarely, if ever dependent on a “single driver mutation”. This makes the disease challenging to treat, as targeting one single abnormal gene or just one pathway is unlikely to result in a cure.
B. Considerable genetic heterogeneity exists even for this single histopathologic entity, implying multiple possible causative pathways, and variability in terms of response to treatment. This heterogeneity has now been explored in large datasets, allowing prognostic grouping of patients into 3 to 4 distinct classes; theories are emerging as to which pathways and drugs maybe best for the various classes, and clinical trials to test these theories are being pursued.
C. There are some preliminary data allowing us to understand an association between certain therapies and the presence/absence of certain molecular and genetic features which can be either prognostic, or sometimes even predictive markers for certain therapies; example sof this include MGMT methylation status, IDH mutation status, 1p19q deletion status, etc. The exact mechanisms underlying these findings are still being worked out, but the data are resulting in some degree of customization of therapy.
D. In certain lower grade gliomas, especially in children, targeted agents are already being pursued, with good early promising results.
A. Unlike some other tumors, GBM is characterized by multiple genetic modifications, and is rarely, if ever dependent on a “single driver mutation”. This makes the disease challenging to treat, as targeting one single abnormal gene or just one pathway is unlikely to result in a cure.
B. Considerable genetic heterogeneity exists even for this single histopathologic entity, implying multiple possible causative pathways, and variability in terms of response to treatment. This heterogeneity has now been explored in large datasets, allowing prognostic grouping of patients into 3 to 4 distinct classes; theories are emerging as to which pathways and drugs maybe best for the various classes, and clinical trials to test these theories are being pursued.
C. There are some preliminary data allowing us to understand an association between certain therapies and the presence/absence of certain molecular and genetic features which can be either prognostic, or sometimes even predictive markers for certain therapies; example sof this include MGMT methylation status, IDH mutation status, 1p19q deletion status, etc. The exact mechanisms underlying these findings are still being worked out, but the data are resulting in some degree of customization of therapy.
D. In certain lower grade gliomas, especially in children, targeted agents are already being pursued, with good early promising results.
Similar Questions
Note: All content on this site is informational and not a substitute for professional medical advice.
Always seek the advice of your physician or other qualified health provider with questions regarding your health.
Note: Usernames have been made anonymous and profile images are not shown to protect the privacy of our members.
Thank you for flagging this content. We will look into it right away.
Add Answer
1) Question:
2) Background Info (optional): What context or background information is relevant to this request?
Notes:
The more clear and thorough your request, the more likely you will receive support.
Many of our members are learning from this information or english might not be their first language. Please use standard english and spell out all words. For example, use 'you' instead of 'u'.
The more clear and thorough your request, the more likely you will receive support.
Many of our members are learning from this information or english might not be their first language. Please use standard english and spell out all words. For example, use 'you' instead of 'u'.
Newsletters
Share Conversation
To tell people about this conversation, type their email addresses here (separated by commas):
From:
Add a personal note here:
Brain Cancer Updates
Sign up for our
Brain Cancer
updates for the latest news, best answers and featured experts.
Ads keep TalkAboutHealth freeadvertisement
Similar Questions
Updates
Sign up for email updates of the latest news, best answers, and featured experts.
Benefits
Custom health, wellness, & medical offers from our partners including clinical trials, market research opportunities & new programs.
SHARE Support
1) Call SHARE at: 866-891-2392
to speak directly to a trained breast cancer survivor for support and guidance.
2) Direct message the trained peer supporter you select.
3) E-mail us at support@talkabouthealth.com, and we will find the right match for you.
More info
to speak directly to a trained breast cancer survivor for support and guidance.
2) Direct message the trained peer supporter you select.
3) E-mail us at support@talkabouthealth.com, and we will find the right match for you.
More info
3 Quick Ways You Can Help
1) Spread the word! Tell people you think might want some support. Tell medical professionals, health providers, and organizations.
2) Like us on Facebook and follow us on Twitter!
3) Volunteer - email us at volunteer@talkabouthealth.com for more information.
More Ways To Help!
2) Like us on Facebook and follow us on Twitter!
3) Volunteer - email us at volunteer@talkabouthealth.com for more information.
More Ways To Help!
View All Newsletters
